{"id":"opc-14597-aripiprazole","safety":{"commonSideEffects":[{"rate":"10-25%","effect":"Akathisia"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Anxiety"},{"rate":"5-15%","effect":"Insomnia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL1112","moleculeType":"Small molecule","molecularWeight":"448.39"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Aripiprazole acts as a partial agonist rather than a full antagonist, meaning it can both activate and inhibit dopamine D2 receptors depending on baseline dopamine levels, providing a stabilizing effect. This unique mechanism reduces excessive dopaminergic activity in hyperactive states while maintaining adequate dopaminergic function in hypoactive states. The drug also has partial agonist activity at 5-HT1A receptors, contributing to its antipsychotic and mood-stabilizing effects.","oneSentence":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that stabilizes dopaminergic and serotonergic neurotransmission.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:24.541Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Autism spectrum disorder (irritability)"}]},"trialDetails":[{"nctId":"NCT03485417","phase":"PHASE2, PHASE3","title":"Substance Misuse To Psychosis for Stimulants","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-06-01","conditions":"Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence","enrollment":165},{"nctId":"NCT07483294","phase":"","title":"Cerebellum-based Imaging Neural Markers for Antipsychotic Response","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-11-01","conditions":"Psychosis; Acute","enrollment":120},{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT04903353","phase":"PHASE4","title":"Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-02-01","conditions":"Weight Gain, Autism Spectrum Disorder, Medication Side Effect","enrollment":31},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT05662306","phase":"PHASE4","title":"C-Cog in Early Course Schizophrenia Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2024-01-23","conditions":"Schizophrenia","enrollment":1},{"nctId":"NCT03238326","phase":"PHASE3","title":"Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-08-23","conditions":"Schizophrenia","enrollment":295},{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT03442101","phase":"","title":"Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2018-04-01","conditions":"Psychosis","enrollment":156},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06236451","phase":"PHASE4","title":"Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2024-04-05","conditions":"Schizophrenia","enrollment":60},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT07215884","phase":"PHASE1","title":"Dopamine and Sensorimotor Function in Stuttering","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-30","conditions":"Stuttering, Adult","enrollment":40},{"nctId":"NCT00288353","phase":"PHASE3","title":"Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2006-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":48},{"nctId":"NCT05545891","phase":"PHASE2","title":"Aripiprazole in Body Focused Repetitive Behaviors","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06","conditions":"Trichotillomania (Hair-Pulling Disorder), Dermatillomania","enrollment":100},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT07153406","phase":"PHASE3","title":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2025-09-15","conditions":"Depressive Disorder","enrollment":220},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT01490086","phase":"PHASE2","title":"RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Reviva Pharmaceuticals","startDate":"2011-12","conditions":"Acute Schizophrenia, Schizoaffective Disorder","enrollment":234},{"nctId":"NCT05169268","phase":"","title":"Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-02-01","conditions":"Schizophrenia and Related Disorders, Anxiety Depression","enrollment":10},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT07011693","phase":"PHASE4","title":"Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)","status":"NOT_YET_RECRUITING","sponsor":"Xinyu Zhou","startDate":"2025-06-20","conditions":"Major Depressive Disorder (MDD)","enrollment":400},{"nctId":"NCT05686772","phase":"","title":"Prospective Multicenter Cohort Study Evaluating the Incidence and Risk Factors for Problem Gambling Among Young Adults With First-episode Psychosis","status":"COMPLETED","sponsor":"Laval University","startDate":"2019-11-01","conditions":"Gambling Disorder, Psychotic Disorders","enrollment":520},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":"Obsessive-Compulsive Disorder","enrollment":1600},{"nctId":"NCT02752542","phase":"PHASE4","title":"Personalized Indications for CBT and Antidepressants in Treating Depression","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2016-10-31","conditions":"Major Depressive Disorder, Persistent Depressive Disorder","enrollment":80},{"nctId":"NCT06969755","phase":"PHASE4","title":"Biomarkers to Enhance Early Schizophrenia Treatment","status":"NOT_YET_RECRUITING","sponsor":"Northwell Health","startDate":"2025-07-30","conditions":"Schizophenia Disorder","enrollment":180},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03874494","phase":"PHASE3","title":"Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2019-11-27","conditions":"Schizophrenia","enrollment":371},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT01119014","phase":"PHASE4","title":"Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis","status":"COMPLETED","sponsor":"Anne Katrine Pagsberg","startDate":"2010-05","conditions":"Psychosis","enrollment":300},{"nctId":"NCT04812379","phase":"","title":"Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2021-04-07","conditions":"Bipolar Disorder I","enrollment":535},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT06799559","phase":"PHASE3","title":"Study on the Efficacy and Safety of QLM1016 in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-05","conditions":"Schizophrenia","enrollment":402},{"nctId":"NCT05361993","phase":"PHASE4","title":"Efficacy of Biofeedback in the Treatment of Tic Disorder","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2024-06-01","conditions":"Tic Disorders","enrollment":""},{"nctId":"NCT05322031","phase":"PHASE4","title":"The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2022-08-01","conditions":"Schizophrenia, Myelin Degeneration, Cognition Disorder","enrollment":15},{"nctId":"NCT04789915","phase":"PHASE1","title":"Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2021-05-26","conditions":"Psychosis, Negative Symptoms With Primary Psychotic Disorder","enrollment":46},{"nctId":"NCT05942716","phase":"PHASE2","title":"Serotonin Control of Impulsivity in Tourette Disorder","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-24","conditions":"Tourette Disorder","enrollment":25},{"nctId":"NCT05531591","phase":"PHASE4","title":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-08-01","conditions":"Depression, Dementia, Mild Cognitive Impairment","enrollment":87},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06613334","phase":"NA","title":"Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses","status":"RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2024-10-04","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT02960763","phase":"PHASE4","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-24","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression","enrollment":742},{"nctId":"NCT06589817","phase":"PHASE3","title":"A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2024-10","conditions":"Acute Schizophrenia","enrollment":376},{"nctId":"NCT06590298","phase":"PHASE4","title":"Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females","status":"NOT_YET_RECRUITING","sponsor":"Universiti Putra Malaysia","startDate":"2024-09-15","conditions":"Psychosis, Metabolic Syndrome, Weight Gain","enrollment":600},{"nctId":"NCT02918370","phase":"PHASE3","title":"Aripiprazole for Bipolar Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-11","conditions":"Bipolar Disorder, Alcoholism, Alcohol Abuse","enrollment":75},{"nctId":"NCT03423680","phase":"PHASE3","title":"A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression","status":"RECRUITING","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2018-02-22","conditions":"Depression, Bipolar","enrollment":390},{"nctId":"NCT01617460","phase":"PHASE3","title":"A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-09","conditions":"Autistic Disorder","enrollment":86},{"nctId":"NCT06372210","phase":"NA","title":"A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2023-06-26","conditions":"Mental Disorder, Schizophrenia, Major Depressive Disorder","enrollment":54},{"nctId":"NCT06501339","phase":"PHASE4","title":"Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2024-08-10","conditions":"Clozapine Resistant Schizophrenia","enrollment":40},{"nctId":"NCT03522168","phase":"","title":"Long-term Antipsychotic Pediatric Safety Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-01-10","conditions":"Weight, Body","enrollment":509},{"nctId":"NCT06482554","phase":"PHASE3","title":"Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2024-06","conditions":"Apathy, Schizophrenia, Schizophrenia; Psychosis","enrollment":80},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT06467474","phase":"NA","title":"Psychoeducational Group for Depression","status":"RECRUITING","sponsor":"Ricardo Alberto Moreno, M.D., Ph.D.","startDate":"2024-03-01","conditions":"Major Depressive Disorder (MDD","enrollment":338},{"nctId":"NCT06373770","phase":"NA","title":"Effects of Ayres Sensory Integration Therapy Versus Conservative Treatment in Autism Spectrum","status":"ACTIVE_NOT_RECRUITING","sponsor":"Superior University","startDate":"2023-10-01","conditions":"Autism Spectrum Disorder","enrollment":30},{"nctId":"NCT06054321","phase":"NA","title":"Psychopharmacotherapy for Depressive Patients","status":"RECRUITING","sponsor":"Chonnam National University Hospital","startDate":"2022-08-03","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT02822092","phase":"","title":"Striatal Connectivity and Clinical Outcome in Psychosis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2016-07","conditions":"Psychotic Disorders","enrollment":196},{"nctId":"NCT05389046","phase":"NA","title":"Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-08-15","conditions":"Outpatients / Inpatients With Depression","enrollment":252},{"nctId":"NCT05554627","phase":"PHASE4","title":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2023-10-27","conditions":"Depressive Disorder, Major","enrollment":""},{"nctId":"NCT03198078","phase":"PHASE3","title":"Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-06-30","conditions":"Schizophrenia","enrollment":316},{"nctId":"NCT04203056","phase":"PHASE4","title":"Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2019-12-16","conditions":"Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder","enrollment":15},{"nctId":"NCT04030143","phase":"PHASE1, PHASE2","title":"A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-08-01","conditions":"Schizophrenia, Bipolar I Disorder","enrollment":266},{"nctId":"NCT02357849","phase":"PHASE4","title":"Fluoxetine vs Aripiprazole Comparative Trial (FACT)","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2014-07","conditions":"Attenuated Psychosis Syndrome","enrollment":9},{"nctId":"NCT06128408","phase":"","title":"The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset","status":"UNKNOWN","sponsor":"Peking University","startDate":"2023-12-01","conditions":"Treatment-resistant Schizophrenia","enrollment":300},{"nctId":"NCT00202007","phase":"PHASE2","title":"Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2005-02","conditions":"Schizophrenia","enrollment":240},{"nctId":"NCT06060886","phase":"PHASE4","title":"Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis","status":"UNKNOWN","sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","startDate":"2023-11-01","conditions":"Schizophrenia, Treatment-resistant Schizophrenia, Side Effect","enrollment":244},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT05473741","phase":"","title":"Risk of Breakthrough Symptoms With Long-Acting Injectable Medications","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-01-09","conditions":"Schizophrenia, Schizophrenia Relapse","enrollment":180},{"nctId":"NCT05974241","phase":"PHASE4","title":"Irritability in Children With ADHD and Emotion Dysregulation","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2017-04-21","conditions":"Irritable Mood, ADHD","enrollment":36},{"nctId":"NCT05766540","phase":"PHASE4","title":"Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-08-20","conditions":"Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia","enrollment":60},{"nctId":"NCT05868720","phase":"NA","title":"EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-07-01","conditions":"The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level","enrollment":42},{"nctId":"NCT04312503","phase":"","title":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-07-13","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT00261443","phase":"PHASE4","title":"A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-09","conditions":"Bipolar Disorder","enrollment":1270},{"nctId":"NCT05804721","phase":"PHASE1","title":"Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-10-10","conditions":"Healthy","enrollment":29},{"nctId":"NCT05103410","phase":"PHASE4","title":"Impact of Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-11-10","conditions":"Anesthesia, Analgesia, Hysterotomy","enrollment":80},{"nctId":"NCT03919994","phase":"","title":"Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2019-03-28","conditions":"Schizophrenia","enrollment":338},{"nctId":"NCT05646264","phase":"PHASE4","title":"A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2023-01-01","conditions":"Schizophrenia, Negative Symptoms in Schizophrenia","enrollment":220},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT01354353","phase":"PHASE1","title":"A Study of Safety and Tolerability in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT02955654","phase":"NA","title":"Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder","status":"WITHDRAWN","sponsor":"Shanghai Mental Health Center","startDate":"2017-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":""},{"nctId":"NCT05532254","phase":"PHASE1","title":"Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2021-02-14","conditions":"Healthy Subjects","enrollment":31},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT01328093","phase":"PHASE3","title":"A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients","status":"TERMINATED","sponsor":"Denovo Biopharma LLC","startDate":"2011-04","conditions":"Schizophrenia","enrollment":678},{"nctId":"NCT00276978","phase":"PHASE3","title":"Aripiprazole Augmentation Therapy in Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"University Hospital Freiburg","startDate":"2005-06","conditions":"Therapy-resistant Depression","enrollment":""},{"nctId":"NCT00448630","phase":"","title":"An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10-23","conditions":"Schizophrenia, Metabolic Syndrome X","enrollment":328},{"nctId":"NCT02977299","phase":"PHASE4","title":"Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-01","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":278},{"nctId":"NCT04907279","phase":"","title":"Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)","status":"UNKNOWN","sponsor":"Otsuka Canada Pharmaceutical Inc.","startDate":"2021-11-01","conditions":"Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder","enrollment":200},{"nctId":"NCT00484471","phase":"PHASE4","title":"ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness","status":"COMPLETED","sponsor":"Korea Otsuka International Asia Arab","startDate":"2007-10","conditions":"Bipolar Disorder","enrollment":127},{"nctId":"NCT03408873","phase":"PHASE4","title":"CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)","status":"COMPLETED","sponsor":"Martha Sajatovic","startDate":"2018-04-01","conditions":"Bipolar Disorder, Medication Adherence, Medication Non Adherence","enrollment":30},{"nctId":"NCT03386851","phase":"","title":"Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2016-12-13","conditions":"Schizophrenia, Bipolar 1 Disorder","enrollment":1030},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT00468130","phase":"NA","title":"Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2006-05","conditions":"Autism","enrollment":13},{"nctId":"NCT01123707","phase":"PHASE3","title":"To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-11-18","conditions":"Major Depressive Disorder (MDD)","enrollment":173}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5791,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OPC-14597 (Aripiprazole)","genericName":"OPC-14597 (Aripiprazole)","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that stabilizes dopaminergic and serotonergic neurotransmission. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}